Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsParkland Breyanzi Prior Auth Update | OpenPayer
    Ask Trek AI about this page
    ModifiedParkland Community Health PlanPolicy N/A

    Updated Prior Authorization Criteria for Lisocabtagene Maraleucel (Breyanzi)

    Customize your policy alerts

    Sign up for all parklandcommunityhealthplan policy alerts

    Know when parklandcommunityhealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Texas Medicaid prior authorization and reimbursement requirements for lisocabtagene maraleucel (Breyanzi) infusion therapy for adult Medicaid clients with relapsed or refractory mantle cell lymphoma or marginal zone lymphoma. The updated criteria apply to dates of service on or after December 1, 2026.

    Policy Summary
    PayerParkland Community Health Plan
    PolicyUpdated Prior Authorization Criteria for Lisocabtagene Maraleucel (Breyanzi)
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateDecember 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization before lisocabtagene maraleucel (Breyanzi) infusion therapy.
    SourceLink
    POLICY UPDATE CHANGES

    Texas Medicaid is updating prior authorization criteria for lisocabtagene maraleucel (Breyanzi) procedure code Q2054 effective December 1, 2026.

    Q2054Breyanzi procedure code subject to prior authorization
    2Minimum prior therapy lines for mantle cell lymphoma
    2Minimum prior therapy lines for one marginal zone lymphoma pathway
    C8840Additional diagnosis code for specified reimbursement claims
    Adult clientsPopulation described in policy criteria

    Coverage Criteria

    Initial Breyanzi authorization criteria

    Prior authorization may be approved when the adult client meets one of the following diagnosis criteria.

    Qualifying lymphoma pathway

    • Mantle cell lymphoma pathway: The client has relapsed or refractory mantle cell lymphoma and has received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor.At least 2 prior systemic therapy lines; must include a BTK inhibitor
    • Marginal zone lymphoma pathways

      • Prior-therapy pathway: The client received at least two prior lines of systemic therapy, including an anti-CD20 antibody and an alkylating agent.At least 2 prior systemic therapy lines; must include an anti-CD20 antibody and alkylating agent
      • Post-HSCT relapse pathway: The client has relapsed after hematopoietic stem cell transplantation.Relapse after HSCT

    Initial Therapy Criteria

    Initial Breyanzi therapy

    Prior authorization may be approved when the adult client meets one of the following diagnosis criteria.

    Initial authorization pathways

    • Mantle cell lymphoma: The client has relapsed or refractory mantle cell lymphoma and has received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor.At least 2 prior lines; include a BTK inhibitor
    • Marginal zone lymphoma

      • Prior-therapy pathway: The client received at least two prior lines of systemic therapy, including an anti-CD20 antibody and an alkylating agent.At least 2 prior lines; include an anti-CD20 antibody and alkylating agent
      • Post-HSCT relapse pathway: The client has relapsed after hematopoietic stem cell transplantation.Relapse after HSCT

    Procedure and Diagnosis Coding

    Procedure codeHCPCS
    Q2054lisocabtagene maraleucel (Breyanzi)
    Additional diagnosis code for reimbursementICD-10
    C8840additional diagnosis code
    Prior systemic therapy for mantle cell lymphoma
    DiagnosisRelapsed or refractory mantle cell lymphoma
    Minimum prior therapyAt least 2 prior lines of systemic therapy
    Required treatment elementAt least 1 prior line must include a Bruton tyrosine kinase (BTK) inhibitor
    Prior systemic therapy for marginal zone lymphoma
    DiagnosisRelapsed or refractory marginal zone lymphoma
    Minimum prior therapyAt least 2 prior lines of systemic therapy
    Required agentsPrior therapy must include an anti-CD20 antibody and an alkylating agent

    Provider Actions

    Prior Authorization

    Obtain prior authorization before Breyanzi infusion

    Prior authorization is required for lisocabtagene maraleucel (Breyanzi) infusion therapy. Approval may be granted for an adult client with relapsed or refractory mantle cell lymphoma who has received at least two prior lines of systemic therapy, including a BTK inhibitor, or for relapsed or refractory marginal zone lymphoma meeting either specified prior-therapy pathway or post-HSCT relapse pathway.

    • Mantle cell lymphoma: at least two prior systemic therapy lines, including a Bruton tyrosine kinase inhibitor.
    • Marginal zone lymphoma: at least two prior systemic therapy lines, including an anti-CD20 antibody and alkylating agent, or relapse after hematopoietic stem cell transplantation.
    Documentation Required

    Document diagnosis and treatment history

    Submit documentation supporting the diagnosis of relapsed or refractory mantle cell lymphoma or marginal zone lymphoma and the applicable treatment history. Include the required prior therapies and agents, or documentation of relapse after hematopoietic stem cell transplantation, as applicable.

    • Mantle cell lymphoma: document at least two prior lines of systemic therapy, including a BTK inhibitor.
    • Marginal zone lymphoma: document at least two prior lines including an anti-CD20 antibody and alkylating agent, or relapse after HSCT.
    Billing Rule

    Use the required claim codes

    For reimbursement, submit lisocabtagene maraleucel (Breyanzi) procedure code Q2054 with the additional diagnosis code C8840.

    • Procedure code: Q2054 — lisocabtagene maraleucel (Breyanzi).
    • Additional diagnosis code: C8840.
    Denial Risk

    Prevent denial by confirming qualifying history

    Prior authorization may be denied when the client does not meet a complete lymphoma-specific qualifying pathway. This includes insufficient prior therapy for mantle cell lymphoma or failure to meet either the required prior-therapy pathway or the post-HSCT relapse pathway for marginal zone lymphoma.

    • Mantle cell lymphoma: denial risk applies if the client has not received at least two prior lines of systemic therapy, including a BTK inhibitor.
    • Marginal zone lymphoma: the client must have at least two prior systemic therapy lines including an anti-CD20 antibody and alkylating agent, or documented relapse after HSCT.

    Therapy Background

    Lisocabtagene maraleucel (Breyanzi) is an FDA-approved cellular immunotherapy for adult clients with relapsed or refractory marginal zone lymphoma who have received at least two prior lines of systemic therapy. This policy also establishes prior authorization criteria for adult clients with relapsed or refractory mantle cell lymphoma, including prior treatment with a Bruton tyrosine kinase inhibitor. The updated requirements apply to Texas Medicaid dates of service on or after December 1, 2026.

    Key Definitions

    BTK inhibitor
    Full termBruton tyrosine kinase inhibitor
    Therapy typeSystemic therapy
    Mantle cell lymphoma requirementA BTK inhibitor must be included among the prior treatment lines for the qualifying relapsed or refractory mantle cell lymphoma pathway
    HSCT
    Full termHematopoietic stem cell transplantation
    AbbreviationHSCT
    Marginal zone lymphoma pathwayRelapse after HSCT is an alternative qualifying pathway for relapsed or refractory marginal zone lymphoma
    Policy Summary
    PayerParkland Community Health Plan
    PolicyUpdated Prior Authorization Criteria for Lisocabtagene Maraleucel (Breyanzi)
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateDecember 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization before lisocabtagene maraleucel (Breyanzi) infusion therapy.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaProcedure and Diagnosis CodingProvider ActionsTherapy BackgroundKey Definitions

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.